Lecanemab appropriate use recommendations for clinical practice in the UK. — Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in adults who are apolipoprotein E ε4 gene (APOE4)...

Evidence span

Lecanemab appropriate use recommendations for clinical practice in the UK. — Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in adults who are apolipoprotein E ε4 gene (APOE4)...

From Mummery CJ et al. 2026, Journal of neurology, neurosurgery, and psychiatry

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

Homo sapiens

Conditions

Humans; Alzheimer Disease; Magnetic Resonance Imaging; Apolipoprotein E4; Amyloid beta-Peptides — Journal of neurology, neurosurgery, and psychiatry 2026

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required